These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23172047)

  • 1. When falsified medicines enter the supply chain: description of an incident in Kenya and lessons learned for rapid response.
    Cohn J; von Schoen-Angerer T; Jambert E; Arreghini G; Childs M
    J Public Health Policy; 2013 Jan; 34(1):22-30. PubMed ID: 23172047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab.
    Petersen A; Held N; Heide L;
    PLoS One; 2017; 12(9):e0184165. PubMed ID: 28877208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The Herceptin® case : A case of falsification of medicinal products to a greater extent].
    Streit R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Nov; 60(11):1203-1207. PubMed ID: 28936679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Right to health encompasses right to access essential generic medicines: challenging the 2008 Anti-Counterfeit Act in Kenya.
    Maleche A; Day E
    Health Hum Rights; 2014 Dec; 16(2):E96-E104. PubMed ID: 25569728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Falsified medicines in parallel trade].
    Muckenfuß H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Nov; 60(11):1208-1213. PubMed ID: 28905079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [securPharm e. V. - a protective shield against falsified medicines].
    Bergen M; Hoferichter R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Nov; 60(11):1255-1260. PubMed ID: 28929207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Point-of-Care Anti-Counterfeit Medicines Technologies: Awareness and Utilization among Medical Practitioners in Eastern Nigeria.
    Iloh GU; Akodu BA; Emeka EA; Obi IV
    West Afr J Med; 2021 Nov; Vol. 38(11):1029-1035. PubMed ID: 34918894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elixirs of death. International organizations are working towards a global solution to address the problem of falsified and substandard medicines, but progress has stagnated.
    Weigmann K
    EMBO Rep; 2013 Jul; 14(7):597-600. PubMed ID: 23764922
    [No Abstract]   [Full Text] [Related]  

  • 9. Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance.
    Pisani E; Hasnida A; Rahmi M; Kok MO; Harsono S; Anggriani Y
    JMIR Public Health Surveill; 2021 Aug; 7(8):e29309. PubMed ID: 34181563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Legal aspects of counteracting the trafficking of falsified medicines in the european union.
    Pashkov V; Soloviov A; Olefir A
    Wiad Lek; 2017; 70(4):843-849. PubMed ID: 29064815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Counterfeit and Falsified Drugs: an Overview].
    Taverriti-Fortier C; Pape E; Scala-Bertola J; Tréchot P; Maincent P; Gibaja V; Gambier N
    Therapie; 2015; 70(5):455-64. PubMed ID: 26071144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current cases of falsified medicinal products within the competence of the Federal Institute for Drugs and Medical Devices (BfArM) : Case studies and extent].
    Wittstock M; Paeschke N
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Nov; 60(11):1196-1202. PubMed ID: 28980029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the return on investment of technologies to detect substandard and falsified amoxicillin: A Kenya case study.
    Higgins CR; Kobia B; Ozawa S
    PLoS One; 2023; 18(1):e0268661. PubMed ID: 36652447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Substandard and Falsified Medicines: Influence of Different Tolerance Limits and Use of Authenticity Inquiries.
    Hauk C; Hagen N; Heide L
    Am J Trop Med Hyg; 2021 Mar; 104(5):1936-1945. PubMed ID: 33788775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies.
    Hamilton WL; Doyle C; Halliwell-Ewen M; Lambert G
    Health Policy Plan; 2016 Dec; 31(10):1448-1466. PubMed ID: 27311827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic cost of substandard and falsified human medicines and cosmetics with banned ingredients in Tanzania from 2005 to 2015: a retrospective review of data from the regulatory authority.
    Mori AT; Meena E; Kaale EA
    BMJ Open; 2018 Jun; 8(6):e021825. PubMed ID: 29950474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Task force for falsified medicines].
    Weber G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Nov; 60(11):1240-1244. PubMed ID: 28905078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Global Wicked Problem of Corruption and Its Risks for Access to HIV/AIDS Medicines.
    Kohler JC; Chang Pico T; Vian T; Mackey TK
    Clin Pharmacol Ther; 2018 Dec; 104(6):1054-1056. PubMed ID: 30076604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.
    Ozawa S; Evans DR; Bessias S; Haynie DG; Yemeke TT; Laing SK; Herrington JE
    JAMA Netw Open; 2018 Aug; 1(4):e181662. PubMed ID: 30646106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of existing and emerging digital technologies to combat the global trade in fake medicines.
    Mackey TK; Nayyar G
    Expert Opin Drug Saf; 2017 May; 16(5):587-602. PubMed ID: 28349715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.